HIV News and Research

RSS

Study looking at impact of HIV funding on Rwanda's health system has 'serious limitations'

In this post on the Center for Global Development's (CGD) "Global Health Policy" blog, Research Fellow Victoria Fan, Director of Global Health Policy Amanda Glassman, and Research Assistant Rachel Silverman of the Center for Global Development (CGD) examine what they call the "serious limitations" of a study published recently in the American Journal of Tropical Medicine & Hygiene that looked at the impact of HIV/AIDS funding on Rwanda's health system.

11 May 2012

FDA panel recommends approval of Truvada as preventive treatment for HIV

"In a move that could lead to a new milestone for treatment in the evolution of the worldwide AIDS epidemic," a Food and Drug Administration (FDA) panel on Thursday recommended Gilead Sciences' Truvada as a treatment for preventing HIV infection among healthy people at risk of contracting the virus, Reuters reports, noting, "It already has FDA approval to treat people infected with the human immunodeficiency virus".

11 May 2012

U.S. investment in global health has been successful, deserves continued congressional support

"Over the next few weeks, appropriators will be engaged in the challenging task of evaluating U.S. foreign assistance funding, including how effectively Congress' global health investments are being used," Charles Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation; Molly Joel Coye, interim president and CEO of PATH; Carolyn Miles, president and CEO of Save the Children; and Richard Stearns, president of World Vision, write in this Roll Call opinion piece.

11 May 2012

Algeria, UNAIDS to build first HIV/AIDS research center in MENA region

"Algeria will partner with the Joint United Nations Programme on HIV/AIDS (UNAIDS) to build the first HIV/AIDS research center in the Middle East and North Africa (MENA)," Nature Middle East reports.

11 May 2012

HIV prevention drug receives FDA panel's backing

The drug has already been approved as a treatment for HIV/AIDS. The FDA is expected to decide about approval by June 15.

11 May 2012

Safer indoor sex work spaces promote health and safety of street-involved women

Safer indoor sex work spaces provide important and potentially life-saving benefits to sex workers including reduced exposure to violence and HIV and improved relationships with police, according to a study published by the Gender and Sexual Health Initiative of the BC Centre for Excellence in HIV/AIDS (BC-CfE) and the University of British Columbia.

11 May 2012

This Mother's Day, ensure babies everywhere are born free of HIV

Ahead of Mother's Day on May 13, UNAIDS Executive Director Michel Sidibe writes in this post in the Huffington Post's "Global Motherhood" blog, "Together we can go from 390,000 children becoming infected with HIV each year to zero," and he highlights "three simple things we can all do to ensure babies everywhere can be born free from HIV."

11 May 2012

MSF says additional resources needed to improve ART access in Burma

Medecins Sans Frontieres (MSF), the largest provider of antiretroviral treatment (ART) in Burma, also known as Myanmar, are calling for the gap between the need for and access to ART in the country to be closed, the Guardian reports.

11 May 2012

Female Presidents of Liberia, Malawi pledge to address gender equality, improve women's health

"The only two female heads of state in Africa, Liberian President Ellen Johnson Sirleaf and Malawian President Joyce Banda, have just committed to using their positions to improve the lives of women across the continent," Inter Press Service reports.

11 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

USAID launches five-year initiative in Nigeria to strengthen HIV, TB services

U.S. Ambassador to Nigeria Terence McCulley on Tuesday in Abuja, Nigeria, launched a five-year, $224 million USAID program, titled Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS), that aims to "increase access to high-quality comprehensive HIV/AIDS and tuberculosis prevention, treatment, care and related services through improved efficiencies in service delivery," the Daily Trust reports.

10 May 2012

Leishmaniasis vaccine trial begins in U.S., India

"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it is found most commonly in India, Nepal, Bangladesh, Brazil and Sudan," the news service notes.

10 May 2012

UNAIDS launches campaign aimed at ending new HIV infections among children by 2015

UNAIDS on Tuesday launched a new campaign "aimed at ending new HIV infections among children by 2015 and ensuring mothers living with HIV remain healthy," Xinhua reports.

10 May 2012

NCATS initiative to use abandoned experimental drugs for other uses 'a step in the right direction'

The National Institutes of Health's (NIH) National Center for Advancing Translational Science (NCATS) -- a new plan to help speed drug development by making abandoned experimental drugs available to researchers who can look for alternative uses -- "is an indication that the Obama administration and the medical research enterprise are thinking out of the box," Michael Manganiello, a partner at HCM Strategists, writes in a Huffington Post "Politics Blog" opinion piece.

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

Treatment with IL-12 triggers T cell exhaustion in cancer patients

Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found.

10 May 2012

ACOEM honors JNJ with 2012 Corporate Health Achievement Award

Johnson & Johnson (JNJ) the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services for the consumer and pharmaceutical and medical devices and diagnostics markets, has been awarded the 2012 Corporate Health Achievement Award (CHAA) by the American College of Occupational and Environmental Medicine.

10 May 2012